© 2019 Mercy IMR Medicine Chiefs

Hematology Curriculum 

Hematology Service

Acute Myeloid Leukemia

Cytogenetics in acute Leukemia

Acute Myeloid leukemia and acute promyelocytic leukemia

Novel therapies in acute myeloid leukemia

All-trans-retinoic acid as a differentiating agent in treatment of promyelocytic leukemia

Anemia

Diagnosis from a Blood Smear

Anticoagulation

Peri-operative Management of Patients Who Are Receiving Coumadin Therapy 

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Treatment of Philadelphia Chromosome Positive, Accelerated Phase Chronic Myelogenous Leukemia with Imatinib

Lymphoma

Hodgkin's Lymphoma; Diagnosis and Treatment

Rituximab-CHOP vs CHOP Alone in Older Patients with Diffuse Large B Cell

Antibacterial Prophylaxis after Chemotherapy for Solid Tumors

Tumor Lysis Syndrome

Anti-CD20 Therapy for B cell Lymphomas

Myleodysplastic Syndrome

Myleodysplastic Syndrome

The Myelodysplastic Syndrome(s): Perspective and Review

Multiple Myeloma

Multiple Myleoma

Thrombocytopenia

Treatment and Prevention of Heparin Induced Thrombocytopenia

Low Molecular Heparin Compared with Intravenous Unfractionated Heparin for Pulmonary Embolism

Oncology Service

Brain Metasis

Molecular Basis of Metastasis

Cancer Biology

Cancer Stem Cells

Molecular Basis of Colorectal Cancer

Cancer of Unknown Primary

Treatment of Patients with Cancer of Unknown Primary

ASCO 2006 Updated of Recommendations for the Use of Tumors Markers

Hem/Onc Emergencies

Oncologic Emergencies: Diagnosis and Treatment

The Tumor Lysis Syndrome

Hypercalcemia Associated with Cancer

Lung Cancer

Twenty Years of Phase III Trials for Patients with Extensive Small Cell Lung Cancer

Recent Advances in the Diagnosis and Management of Malignant Pleural Effusions

Prostate Cancer

Initial Hormonal Management of Androgen Sensitive Metastatic, Recurrent, or Progressive Prostate Cancer

Renal Cell Carcinoma

Nephrectomy Followed By Interferon Alfa 2b Compared with Interferon Alfa-2a Alone

Management of Toxicities of High Dose Interleukin 2